CABOTEGRAVIR
+ RILPIVIRINE Long-acting
for treatment
|
|
Long-acting
Cabotegravir (CAB) plus
Rilpivirine (RPV) in the
first,
virologically-suppressed
adolescents with HIV-1 to
receive an every 8-week,
all-injectable regimen in
a multicenter,
multinational Study:
IMPAACT 2017 Week 48
Outcomes*
Aditya H. et al. - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
Anti-racist,
anti-sexist, anti-ageist
implementation science
study of long-acting
injectable Cabotegravir
and Rilpivirine in clinic
and community shows
differences for women,
older, and Black
participants: ILANA
Primary Endpoint (M12)
results*
Orkin C. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Subcutaneous
injections of cabotegravir
+ rilpivirine in virally
suppressed adults with
HIV-1: a substudy of the
Phase 3 FLAIR study
D'Amico et al. - Oral
Presentation
|
View
Poster
|
|
Clinical
Outcomes at Month 12 After
Initiation of Cabotegravir
and Rilpivirine Long
Acting (CAB+RPV LA) in an
Observational Real-World
Study (BEYOND)*
Schneider S. et al. - Poster
|
View
Poster
|
|
Perspectives
of people with HIV (PWH)
12 months following a
switch to cabotegravir and
rilpivirine long-acting
(CAB+RPV LA) in an
observational real-world
US study (BEYOND)
Valenti W. et al. - Poster
|
View
Poster
|
|
12-month
outcomes of cabotegravir
plus rilpivirine
long-acting every 2 months
in a real-world setting:
effectiveness, adherence
to injections, and
patient-reported outcomes
from people with HIV-1 in
the German CARLOS cohort
Jonsson-Oldenbüttel C. et
al. - Poster
|
View
Poster
|
|
Increased
screening for sexually
transmitted infections and
HIV surrogate marker
testing among long-acting
injectable versus daily
oral antiretroviral
therapy users in the OPERA
cohort
Lackey P.C. et al. - Poster
|
View
Poster
|
|
Real-World
Utilization and
Effectiveness of
Long-Acting Cabotegravir +
Rilpivirine in
Virologically Suppressed
Treatment Experienced
Individuals in Europe:
COMBINE-2 Cohort Study
Pozniak A. et al. - Poster
|
View
Poster
|
|
Re-thinking
'community' in the
implementation of
long-acting injectable
Cabotegravir and
Rilpivirine: qualitative
findings from the ILANA
study*
Hayes R. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Adherence
through the prism of
long-acting injectable
therapy: qualitative
findings from the ILANA
implementation study*
Paparini S. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Closer to a
cure: mixed-methods
analysis of reasons for
switching to long-acting
injectable Cabotegravir +
Rilpivirine*
Paparini S. et al. - Poster
|
View
on AIDS 2024 Site
|
|
"I have to
feel comfortable":
Attitudes towards
pharmacy-administered
long-acting injectable
antiretroviral therapy in
a sample of people with
HIV*
Cocohoba J. et al. - Poster
|
View
on AIDS 2024 Site
|
|
CABOTEGRAVIR
Long-acting for prevention
|
|
Evaluation of
Long-Acting Cabotegravir
(CAB-LA) Pharmacokinetics
During Pregnancy: A
Sub-Study Analysis of the
HPTN 084 Open Label
Extension
Marzinke MA et al. - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
Evaluation of
CAB-LA Safety during
pregnancy in the HPTN 084
open-label extension*
Delany-Moretlwe S. et al -
Oral Presentation
|
View
on AIDS 2024 Site
|
|
Performance
characteristics of HIV RNA
screening with long-acting
injectable cabotegravir
(CAB-LA) pre-exposure
prophylaxis (PrEP) in HPTN
083*
Landovitz R. et al - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
Location
preferences for accessing
long-acting injectable
pre-exposure prophylaxis
(LA-PrEP) among men who
have sex with men (MSM)
currently using daily-oral
PrEP
Glick J.L. et al. - Poster
|
View
Poster
|
|
HIV
pre-exposure prophylaxis
awareness, willingness,
and use among
transfeminine persons with
high likelihood of HIV in
the United States: recent
results from the
Transgender Women's
Internet Survey and
Testing (TWIST)
Yeras D.I. et al. - Poster
|
View
Poster
|
|
Preference
for long-acting HIV
prevention methods among
transgender women most at
risk for HIV acquisition
in eastern and southern
United States: findings
from the LITE study
Cooney E.E. et al. - Poster
|
View
Poster
|
|
Influencers
and decision-making
factors for choosing
injectable PrEP among men
who have sex with men and
transgender men in the
United States
Dandachi D. et al. - Poster
|
View
Poster
|
|
Need for
increased HIV testing
prior to and during
pre-exposure prophylaxis
with cabotegravir
long-acting injections in
routine clinical care in
the United States
Hsu R.K. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Pre-Exposure
Prophylaxis Product Choice
of Participants in HPTN
083*
Clement ME et al. - Poster
|
View
on AIDS 2024 Site
|
|
Understanding
Parental Motivations and
Decision-Making for
Adolescent Girls’
Participation in the
long-acting cabotegravir
(CAB-LA) trial – Insights
from HPTN 084-1*
Ndimande-Khoza N. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
Changes in
sexual behavior among
adolescent girls receiving
long-acting injectable
cabotegravir for HIV
prevention; the HPTN
084-01 stud*
Mirembe B.G. et al. - Poster
|
View
on AIDS 2024 Site
|
|
“Everyone
should have access to it”:
Perspectives on PrEP
product choice and
implementation from MSM
and TGW in an injectable
PrEP trial*
Psaros C. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Knowledge,
awareness, feasibility,
and acceptability of
long-acting Cabotegravir
for HIV prevention:
results from the SEARCH
Dynamic Choice HIV
prevention trial*
Kakande E. et al. - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
Early
experiences with usage of
injectable cabotegravir
(CAB-LA) among Kenyan and
Ugandan adults
participating in the
SEARCH Dynamic Choice HIV
Prevention trial: a
qualitative study*
Camlin C.S. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Intention to
use long-acting PrEP among
MSM in Europe – results
from the PROTECT survey
from Spain, Italy,
Germany, France and the
United Kingdom*
Jonas K. et al. - Poster
|
View
on AIDS 2024 Site
|
|
A
psycho-social weather
report in the Netherlands:
Mapping the internalised
homonegativity "storms”
and the sexual
self-efficacy "sunshine"
among MSM and their
ecological associations
with HIV care cascade*
Wang H. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Interest and
intention to use
long-acting injectable
PrEP for HIV (LA-PrEP)
among MSM and trans people
in the Netherlands –
results from the PROTECT
Survey*
Kolstee J. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Preferences
for the provision of oral
and injectable PrEP among
MSM and transgender
persons who discontinued
oral PrEP in Europe*
Zimmermann M.L.H. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
Exploring the
Relationship Between
Comprehensive Sexual
Health Prevention Measures
and the Intent to Use
Long-Acting PrEP among
MSM*
Lozano A. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Mapping PrEP
use cascades in the
Netherlands under the
internalised
homonegativity “storm” and
sexual self-efficacy
“sunshine”: Where do MSM
need an umbrella and where
do they need sunglasses?*
Wang
H. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Awareness,
preferences, and attitudes
towards three types of
pre-exposure prophylaxis
among Chinese MSM: A
national cross-sectional
study*
Lin H. et al. - Poster
|
View
on AIDS 2024 Site
|
|
DOLUTEGRAVIR-based
regimens
|
|
Efficacy of
dolutegravir/lamivudine
(DTG/3TC) in adults with
HIV-1 and isolated
reactive hepatitis B core
antibody (anti-HBc):
results from the phase
3/3b GEMINI-1/-2, STAT,
TANGO, and SALSA studies
Fox D. et al. - Oral
Presentation
|
View
Poster
|
|
Non-inferior
efficacy and less weight
gain when switching to
DTG/3TC than whens
witching to BIC/FTC/TAF in
virologically suppressed
people with HIV (PWH): the
PASODOBLE (GeSIDA 11720)
randomized clinical trial*
Ryan P. et al. -
Presentation
|
View
on AIDS 2024 Site
|
|
PAIRED -
PAtIent Reported
Experiences and perceiveD
benefit of treatment with
dolutegravir/lamivudine -
qualitative interviews:
diverse group of people
with HIV-1 (PWH) reflect
on life and health
Slim J. et al. - Poster
|
View
Poster
|
|
Real-World
Effectiveness and
Tolerability of the 2-Drug
Regimen Dolutegravir and
Lamivudine (DTG/3TC) in
People Living With HIV: A
Systematic Literature
Review and Meta-Analysis
From Clinical Practice
Fraysse J. et al. - Poster
|
View
Poster
|
|
Viral
suppression, viral failure
and safety outcomes in
children and adolescents
on dolutegravir (DTG) in
Europe and Thailand
Scott K. et al. - Oral
Presentation
|
View
Poster
|
|
Changes in
body mass index in
children and adolescents
in Europe and Thailand
before and after starting
dolutegravir and compared
to protease inhibitors
using propensity scoring
analysis
Crichton S. et al. - Poster
|
View
Poster
|
|
Prenatal
dolutegravir-based regimen
use, and pregnancy and
birth outcomes: data from
the Antiretroviral
Pregnancy Registry
Vannappagari V. et al. -
Poster
|
View
Poster
|
|
Effectiveness
and durability of
dolutegravir/lamivudine in
older people with HIV from
the Veterans Aging Cohort
Study (VACS)
Yan L. N. et al. - Poster
|
View
Poster
|
|
Effectiveness
and durability of
dolutegravir/rilpivirine
(JULUCA) in older people
with HIV from the Veterans
Aging Cohort Study (VACS)
Yan L. et al. - Poster
|
View
Poster
|
|
Switch to
dolutegravir/lamivudine
(DTG/3TC) in people living
with HIV-1 suppressed on
bictegravir/emtricitabine/tenofovir
alafenamide (B/F/TAF):
96-week final analysis
from the SOUND study*
Slim J. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Efficacy,
safety and tolerability of
switching to
dolutegravir/lamivudine in
virologically suppressed
adults living with HIV on
bictegravir/emtricitabine/tenofovir alafenamide-48-week results from the
DYAD study*
Paige Rolle C. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
Study of a
randomised switch to
DTG/RPV in subjects with
HIV RNA <50c/ml and
archived K103N (Wisard
study): Week 96 follow-up
results*
Moyle G. et al - Poster
|
View
on AIDS 2024 Site
|
|
Differences
between integrase strand
transfer inhibitors on
glucose tolerance: a role
for mitochondrial stress*
Gisbert-Ferrandiz L. et al.
- Poster
|
View
on AIDS 2024 Site
|
|
Differential
Effects of TAF, TDF and
3TC on Murine Weight, Body
Composition and Adipocyte
Differentiation*
García-Martínez P. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
Efficacy of
Dolutegravir Based Single
Tablet Regimen in People
with HIV who inject Drugs*
Alvarez E. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Extended
efficacy and safety of
dolutegravir and darunavir
containing regimens at
week 96 in D2EFT*
Kumarasamy N. et al. - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
D2EFT Body
Composition Sub-study week
96 results*
Carey D. - Poster
|
View
on AIDS 2024 Site
|
|
Dolutegravir
vs Efavirenz: Comparison
and factors associated
with viral blips in an
acute HIV infection cohort
study*
Sacdalan C. et al. - Poster
|
View
on AIDS 2024 Site
|
|
Pipeline
|
|
Preclinical
assessments of a
cabotegravir prodrug
predicting human dosing
durations of >6 months
Baker M. et al. - Poster
|
View
Poster
|
|
Phase 1 study
of VH4524184 (VH-184), a
new third-generation
integrase strand transfer
inhibitor (INSTI) with a
unique resistance profile
Rogg L. et al. - Oral
Presentation
|
View
Poster
|
|
Pre-clinical
profiles of HIV-1 capsid
inhibitors VH4004280
(VH-280) and VH4011499
(VH-499)
Wang C. et al. - Poster
|
View
Poster
|
|
Clinical
pharmacokinetics and
safety of orally
administered VH4004280
(VH-280), a novel HIV-1
capsid inhibitor, in
healthy volunteers
Griesel R. et al. - Poster
|
View
Poster
|
|
Clinical
pharmacokinetics and
safety of orally
administered VH4011499
(VH-499), a novel HIV-1
capsid inhibitor, in
healthy volunteers
Thakkar N. et al. - Poster
|
View
Poster
|
|
Other
HIV-related data
|
|
Detailed
modelling of viremia
exposure does not
independently predict
cardiovascular disease in
people with HIV
Elvstam O. et al. - Oral
Presentation
|
View
Poster
|
|
Intervention
to improve HIV continuous
care monitoring in
public-sector HIV care
sites in São Paulo,
Brazil: A pre-post
implementation evaluation*
Fonsi M. et al. - ePoster
|
View
on AIDS 2024 Site
|
|
Increased
biomarkers of
cardiovascular disease in
a long-term survivor
cohort of young adults
living with perinatal HIV
with virologic
non-suppression or
metabolic syndrome*
Aurpibul L. et al. - Oral
Presentation
|
View
on AIDS 2024 Site
|
|
“A photo is
not enough”: Limitations
of telemedicine based on
qualitative analysis of
interviews with people
living with HIV using this
strategy in the public
health system of Buenos
Aires city*
Kierszenowicz T. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
“They care
about us”: Assessment of
telemedicine by people
with HIV using this
strategy in the public
health system of Buenos
Aires city*
Kierszenowicz T. et al. -
Poster
|
View
on AIDS 2024 Site
|
|
Prioritising
issues for intervention to
improve the health-related
quality of life of people
with HIV: a network
analysis*
Fuster-RuizdeApodaca M.J. et
al. - Poster
|
View
on AIDS 2024 Site
|
|
Resilient
Viral Load Suppression in
an Acutely-Treated Cohort
of People with HIV During
the COVID-19 Pandemic in
Bangkok, Thailand*
Chomchey N et al. - Poster
|
View
on AIDS 2024 Site
|
|
Inside Out:
Inflammation in Acute HIV
Predicts Persistent
Depressive Symptoms
Despite Antiretroviral
Therapy*
Chavez J.V. et al. - Poster
|
View on
AIDS 2024 Site
|
Kollegen Fragen
Diese Seite weiter empfehlen
